 |
|
|
| |
High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated With Direct-Acting Antivirals
|
| |
| |
Reported by Jules Levin
EASL 2016 Barcelona April 14-17
Eric Lawitz1, Kris Kowdley2, Michael Curry3, Nancy Reau4, Mindie Nguyen5, Paul Kwo6, Ira Jacobson7, Tram T. Tran8, Ronald Nahass9, Federico Hinestrosa10, Robert Herring Jr.11, Michael Bennet12, Jenny C. Yang13, Luisa M. Stamm13, Di An13, Hadas Dvory-Sobol13, Diana M. Brainard13, John G. McHutchison13, Eugene Schiff14, Mitchell Davis15, Kyle Etzkorn16, Raymond T. Chung17, David Pound18, Maribel Rodriguez-Torres19, K. Rajender Reddy20, Ziad Younes21, Edward J.Gane22
1Texas Liver Institute, San Antonio, Texas, USA; 2Swedish Medical, Seattle, Washington, USA; 3Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 4Rush University Medical Center, Chicago, Illinois, USA; 5Stanford University, Palo Alto, California, USA; 6Indiana University School of Medicine, Indianapolis, USA; 7Mount Sinai Beth Israel, New York, USA; 8Cedars Sinai Medical Center, Los Angeles, California; 9ID Care, Hillsborough, New Jersey, USA; 10Orlando Immunology Center, Florida, USA; 11Nashville Gastrointestinal Specialists Inc., Tennessee, USA; 12Medical Associates Research Group, Inc., San Diego, California; 13Gilead Sciences, Inc., Foster City, California; 14University of Miami, Florida, USA; 15Digestive CARE-South Florida Center of Gastroenterology, Wellington, Florida, USA; 16Borland-Groover Clinic, Jacksonville, Florida, USA; 17Massachusetts General Hospital, Boston, Massachusetts; 18Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, USA; 19Fundación De Investigación De Diego, San Juan, Puerto Rico; 20University of Pennsylvania , Philadelphia, USA; 21Gastro One, Germantown, Tennessee, USA; 22Auckland Clinical Studies, New Zealand
|
| |
|
|
|
|
|
